Clinical Trial Update: AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease [Phase 3]

View source ↗

Summary

Phase 3 extension study evaluating pioglitazone for slowing cognitive decline in mild cognitive impairment due to Alzheimer's disease; study terminated with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment Due to Alzheimer Disease

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Takeda | Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2019-07-02